In the News
Researchers from the University of Pennsylvania School of Dental Medicine and University of Florida have worked to develop a therapy to prevent these antibodies from developing, using a protein drug produced in plant cells to teach the body to tolerate rather than block the clotting factor.
Roland Herzog, Ph.D., Named next Editor-in-Chief for ASGCT’s Online Journal
Roland Herzog, Ph.D., was recently announced as the next Editor-in-Chief for the American Society of Gene Cell and Therapy’s second open access, online-only journal, Molecular Therapy: Methods & Clinical Development (MTM). Its publications committee was charged with reviewing the applicants and recommending a single candidate to the board of directors.
“Dr. Herzog’s experience currently serving as Deputy Editor for the Society’s official journal, Molecular Therapy, and as Treasurer of the American Society of Gene & Cell Therapy make him especially qualified for this position,” said Helen E. Heslop, M.D., ASGCT Publications Committee Chair.
Dr. Herzog’s five-year term will begin in 2015.
Researchers from University of Florida Health and the University of Pennsylvania have developed a way to thwart production of these antibodies by using plant cells to teach the immune system to tolerate rather than attack the clotting factors. The study was published today (Sept. 4) in the journal Blood.
A fraction of patients with a common form of the bleeding disorder hemophilia develop an allergic reaction to the blood-clotting treatment they need to keep them alive. Using gene therapy, University of Florida researchers were able to reverse this reaction and provide long-lasting treatment for the disease.
UF researchers work to improve treatments for people who have hemophilia.
“Medical Spotlight” – Hemophilia Research
Dr. Roland Herzog was featured in the “Medical Spotlight” on WCJB-TV 20 News and describes to TV 20′s David Snyder how researchers think a certain protein is the key to dramatically improving life for hemophiliacs.